Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease

Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway

(2017) Masayoshi Suda et al.   PLoS One

Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells

(2017) Soon-Youn Choi et al.   PLoS One

A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis

(2016) Haruya Kawase et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy

(2016) Oleg Tsuprykov et al.   KIDNEY INTERNATIONAL

Stromal cell–derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy

(2016) Satoru Takashima et al.   KIDNEY INTERNATIONAL

DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury

(2016) Jee Eun Lee et al.   LABORATORY INVESTIGATION

Sitagliptin attenuates inflammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition

(2016) CHIEN-HUNG LIN et al.   Experimental and Therapeutic Medicine

Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure

(2016) Daniel F. Arruda-Junior et al.   Frontiers in Physiology

Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart

(2015) Li-Hui Zhang et al.   CARDIOVASCULAR DRUGS AND THERAPY

Potential Role of Dipeptidyl Peptidase IV in the Pathophysiology of Heart Failure

(2015) Thiago Salles et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury

(2015) Sun W Lim et al.   LABORATORY INVESTIGATION

Glucagon-like peptide-1 protects cardiomyocytes from advanced oxidation protein product-induced apoptosis via the PI3K/Akt/Bad signaling pathway

(2015) HUA ZHANG et al.   Molecular Medicine Reports

Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation

(2015) Seung Hee Choi et al.   VASCULAR PHARMACOLOGY

Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

(2015) Jacob A. Udell et al.   DIABETES CARE

AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes

(2014) Magali Balteau et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure

(2014) Nobutaka Koibuchi et al.   Cardiovascular Diabetology

Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen

(2014) Keizo Kanasaki et al.   DIABETES

Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy

(2014) Yuliya Sharkovska et al.   JOURNAL OF HYPERTENSION

Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review

(2014) Liviu Segall et al.   Biomed Research International

Circulating Dipeptidyl Peptidase IV Activity Correlates With Cardiac Dysfunction in Human and Experimental Heart Failure

(2013) Leonardo dos Santos et al.   Circulation-Heart Failure

Renal dysfunction and heart failure: things are seldom what they seem

(2013) G. Filippatos et al.   EUROPEAN HEART JOURNAL

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correction: Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms

(2013) Belén Picatoste et al.   PLoS One

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney

(2013) Kwon Wook Joo et al.   BMC Nephrology

Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions

(2012) Toshimasa Shigeta et al.   CIRCULATION

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

(2011) Nelson Gomez et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy

(2011) Lyubov Chaykovska et al.   PLoS One

Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease

(2010) Helmy M. Siragy et al.   AMERICAN JOURNAL OF NEPHROLOGY

Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status

(2010) Terry KW Ma et al.   BRITISH JOURNAL OF PHARMACOLOGY

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

(2010) Bruna PM Pacheco et al.   JOURNAL OF HYPERTENSION

Oxidative stress and left ventricular remodelling after myocardial infarction

(2008) M. Hori et al.   CARDIOVASCULAR RESEARCH

The role of NHE-1 in myocardial hypertrophy and remodelling

(2008) Morris Karmazyn et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY